TITLE

DRUG SAFETY: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed

PUB. DATE
December 2009
SOURCE
GAO Reports;12/9/2009, preceding p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The article discusses the findings of the U.S. Government Accountability Office (GAO) on the oversight of postmarket drug safety by the Food and Drug Administration (FDA). GAO claims that FDA has started to address concerns in its postmarket drug safety management. GAO also admires FDA's move to change its postmarket decision-making process as part of its Safety First Initiative. It further cites plans of FDA to impose new data systems for postmarket drug safety.
ACCESSION #
47027869

 

Related Articles

  • Laying the Foundation. Bush, Laura // BioPharm International;Aug2009, Vol. 22 Issue 8, p10 

    In this article, the author discusses the analysis made by the Government Accountability Office (GAO) on the failure of the Food and Drug Administration (FDA) to meet all its responsibilities in the U.S. The author said that FDA must be able to recognize where the gaps lie to ensure that it is...

  • FDA can't police off-label, says report. B. C. // Medical Marketing & Media;Sep2008, Vol. 43 Issue 9, p9 

    The article focuses on a U.S. Government Accountability Office report on the ability of the U.S. Food and Drug Administration (FDA) to monitor off-label prescription drug promotions. It is noted that the FDA took seven months on average to send regulatory letters to companies promoting drugs for...

  • FDA Faces Challenges Meeting Its Growing Medical Product Responsibilities and Should Develop Complete Estimates of Its Resource Needs.  // GAO Reports;7/20/2009, preceding p1 

    The article reports on the results of an evaluation conducted by the U.S. Government Accountability Office (GAO) on the ability of the Food and Drug Administration (FDA) in meeting its oversight responsibilities on the safety and efficacy of medical products. GAO examined data on the FDA's...

  • Over There. Clinton, Patrick // Pharmaceutical Executive;Nov2008, Vol. 28 Issue 11, p12 

    The author reflects on the ways done by U.S. government agencies in ensuring the safety of imported drugs and other active pharmaceutical ingredients. He cites the study conducted by the Government Accountability Office (GAO) that addressed the approach of the Food and Drug Administration (FDA)...

  • GAO Recommends More FDA Authority on Drug Safety. Sissell, Kara // Chemical Week;5/3/2006, Vol. 168 Issue 15, p28 

    The article presents information on a Government Accountability Office (GAO) report which states that the U.S. Food and Drug Administration (FDA) needs a better system to deal with post-market drug safety problems, and more authority for regulating drugs after the initial FDA approval. GAO...

  • FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. Crosse, Marcia // GAO Reports;10/26/2009, preceding p1 

    The article focuses on a study by the U.S. Government Accountability Office (GAO) on approved drug applications based on surrogate endpoints under Food and Drug Administration's (FDA) accelerated and traditional approval process and the FDA's oversight of postmarketing studies. FDA is...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

Share

Read the Article

Other Topics